HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Combination graft-versus-host disease prophylaxis using immunotoxin (anti-CD5-RTA [Xomazyme-CD5]) plus methotrexate and cyclosporine or prednisone after unrelated donor marrow transplantation.

Abstract
Unrelated donor (URD) bone marrow transplantation (BMT) is associated with more frequent and more therapy-resistant graft-versus-host disease (GVHD). We tested an in vivo immunotoxin with direct cytolytic potency against CD5-expressing T lymphocytes (Xomazyme-CD5) for GVHD prophylaxis after URD BMT. The immunotoxin was given in vivo (0.1 mg/kg/day) for 3 weeks following transplantation in combination with methotrexate+prednisone (MXP; n = 16) or methotrexate+cyclosporine (MCX; n = 6). The 22 patients (10 phenotypically matched with their donors and 12 partially matched) received unmanipulated marrow. MXP was well tolerated, while MCX led to unacceptable nephrotoxicity, weight gain and edema. Four patients died of early complications. Thirteen of 17 evaluable patients achieved myeloid engraftment by 17-40 days (median 24 days). Acute GVHD developed in 9 of 15 evaluable patients (5 grade III/IV). Six of 8 evaluable patients developed chronic GVHD. Four patients survive 1.1-2 years after BMT. Although this immunotoxin has previously shown potency in prophylaxis of murine GVHD and therapy of human GVHD, in this trial inadequate immunosuppressive potency of the immunotoxin combinations was associated with unacceptable clinical toxicity. Aggressive immunoprophylaxis against GVHD is required to improve the success of URD BMT.
AuthorsD Weisdorf, A Filipovich, P McGlave, N Ramsay, J Kersey, W Miller, B Blazar
JournalBone marrow transplantation (Bone Marrow Transplant) Vol. 12 Issue 5 Pg. 531-6 (Nov 1993) ISSN: 0268-3369 [Print] England
PMID8298565 (Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)
Chemical References
  • Antibodies, Monoclonal
  • Immunotoxins
  • XomaZyme
  • Cyclosporine
  • Ricin
  • Prednisolone
  • Methotrexate
Topics
  • Adolescent
  • Adult
  • Antibodies, Monoclonal (adverse effects, therapeutic use)
  • Bone Marrow (immunology, pathology)
  • Bone Marrow Transplantation (immunology, mortality)
  • Child
  • Child, Preschool
  • Cyclosporine (adverse effects, therapeutic use)
  • Drug Therapy, Combination
  • Edema (chemically induced)
  • Female
  • Graft vs Host Disease (mortality, pathology, prevention & control)
  • Histocompatibility
  • Humans
  • Immunotoxins (adverse effects, therapeutic use)
  • Infant
  • Male
  • Methotrexate (adverse effects, therapeutic use)
  • Prednisolone (adverse effects, therapeutic use)
  • Ricin (adverse effects, therapeutic use)
  • Tissue Donors
  • Weight Gain (drug effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: